Outcomes in<unk> s according to clinical stage Clinical stage U.S. five-year survival (%)for 1992–1998 diagnoses Exocrine<unk>  Neuroendocrine treated with surgery IA / I 14 61 IB 12 IIA / II 7 52 IIB 5 III 3 41 IV 1 16<unk>  adenocarcinoma and the other less common exocrine cancers have a very poor prognosis, as they are normally diagnosed at a late stage when the cancer is already locally advanced or has spread to other parts of the body. Outcomes are much better for PanNETs: Many are benign and completely without clinical symptoms, and even those cases not treatable with surgery have an average five-year survival rate of 16%, although the outlook varies considerably according to the type. For locally advanced and metastatic<unk>  adenocarcinomas, which together represent over 80% of cases, numerous trials comparing chemotherapy regimes have shown increased survival times, but not to more than one year. Overall five-year survival for<unk>  in the US has improved from 2% in cases diagnosed in 1975–1977, and 4% in 1987–1989 diagnoses, to 6% in 2003–2009. In the less than 20% of cases of<unk>  adenocarcinoma with a diagnosis of a localized and small cancerous growth (less than 2 cm in Stage T1), about 20% of Americans survive to five years. About 1500 genes are linked to outcomes in<unk>  adenocarcinoma. These include both unfavorable genes, where high expression is related to poor outcome, for example C-Met and MUC-1, and favorable genes where high expression is associated with better survival, for example the transcription factor PELP1.
Pancreatic cancer
Autoimmune pancreatitis
Liver cancer
Duodenal cancer
Gallbladder cancer
Periampullary cancer
Kang cancer
Small intestine cancer